STRUCTURE-FUNCTION RELATIONSHIPS OF LYSOSOMAL ENZYMES

溶酶体酶的结构-功能关系

基本信息

项目摘要

Genetic impairment of ganglioside degradation results in a group of diseases known as the sphingolipidoses. These are very serious disorders that generally cause mental retardation and severely shorten life span. We have been developing mouse models for these disorders through gene disruption in embryonic stem cells. Thus far we have modeled the three types of the GM2 gangliosidoses (Tay-Sachs disease, Sandhoff disease and the GM2 Activator Deficiency) through conventional gene disruption techniques. We are currently developing models of the three clinical types of Gaucher disease using a novel method to insert human disease mutations into embryonic stem cells. The models are being used to identify therapeutic procedures that may be effective in the treatment of these diseases. Currently we are focusing on two approaches, bone marrow transplantation (BMT) and the use of ganglioside synthesis inhibitors. Syngeneic BMT in the Sandhoff disease model has been found to be effective in elongating the life span of the animals (from 4.5 months to 7-8 months) and improving neurologic function. The basis for the therapeutic effect is under investigation. Oral treatment using the ganglioside synthesis inhibitor N-butyldeoxynojirimycin (NB-DNJ) has been found to substantially reduce the level of ganglioside accumulation in the brains of Tay-Sachs disease mice. We are currently testing the efficacy of NB-DNJ in the more severely affected Sandhoff disease model.
神经节苷脂降解的遗传损伤导致一组

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

R L PROIA其他文献

R L PROIA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('R L PROIA', 18)}}的其他基金

STRUCTURE-FUNCTION RELATIONSHIPS OF LYSOSOMAL ENZYMES
溶酶体酶的结构-功能关系
  • 批准号:
    6105753
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
STRUCTURE-FUNCTION RELATIONSHIPS OF LYSOSOMAL ENZYMES
溶酶体酶的结构-功能关系
  • 批准号:
    3855397
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
STRUCTURE-FUNCTION RELATIONSHIPS OF LYSOSOMAL ENZYMES
溶酶体酶的结构-功能关系
  • 批准号:
    3840463
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
STRUCTURE-FUNCTION RELATIONSHIPS OF LYSOSOMAL ENZYMES
溶酶体酶的结构-功能关系
  • 批准号:
    3876427
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
STRUCTURE-FUNCTION RELATIONSHIPS OF LYSOSOMAL ENZYMES
溶酶体酶的结构-功能关系
  • 批准号:
    3964812
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
STRUCTURE-FUNCTION RELATIONSHIPS OF LYSOSOMAL ENZYMES
溶酶体酶的结构-功能关系
  • 批准号:
    5202032
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
STRUCTURE-FUNCTION RELATIONSHIPS OF LYSOSOMAL ENZYMES
溶酶体酶的结构-功能关系
  • 批准号:
    3776923
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
STRUCTURE-FUNCTION RELATIONSHIPS OF LYSOSOMAL ENZYMES
溶酶体酶的结构-功能关系
  • 批准号:
    3941096
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
STRUCTURE-FUNCTION RELATIONSHIPS OF LYSOSOMAL ENZYMES
溶酶体酶的结构-功能关系
  • 批准号:
    4690011
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
STRUCTURE-FUNCTION RELATIONSHIPS OF LYSOSOMAL ENZYMES
溶酶体酶的结构-功能关系
  • 批准号:
    3918242
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Interrogating a Novel Gene Editing Strategy for Predominant Tay-Sachs Disease Mutation
探究泰萨斯病主要突变的新基因编辑策略
  • 批准号:
    466725
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
    Studentship Programs
Analyses of essential interactions of iminosugars with the Hex A active site and evaluation of their pharmacological chaperone effects for Tay-Sachs disease
亚氨基糖与 Hex A 活性位点的基本相互作用分析及其对泰-萨克斯病的药理伴侣效应评估
  • 批准号:
    17K08362
  • 财政年份:
    2017
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Global AAV gene therapy of Tay-Sachs disease in sheep.
绵羊泰萨克斯病的全球 AAV 基因治疗。
  • 批准号:
    9243030
  • 财政年份:
    2016
  • 资助金额:
    --
  • 项目类别:
Global AAV gene therapy of Tay-Sachs disease in sheep.
绵羊泰萨克斯病的全球 AAV 基因治疗。
  • 批准号:
    10063918
  • 财政年份:
    2016
  • 资助金额:
    --
  • 项目类别:
Endoplasmic reticulum quality control of mutant HexA enzyme in Tay-Sachs disease
泰-萨克斯病突变型 HexA 酶的内质网质量控制
  • 批准号:
    8699525
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
Endoplasmic reticulum quality control of mutant HexA enzyme in Tay-Sachs disease
泰-萨克斯病突变型 HexA 酶的内质网质量控制
  • 批准号:
    8593531
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
California Tay-Sachs Disease Prevention Program
加州泰萨斯疾病预防计划
  • 批准号:
    7043056
  • 财政年份:
    2003
  • 资助金额:
    --
  • 项目类别:
DEVELOPMENT OF A MODEL FOR TAY-SACHS DISEASE
泰萨克斯病模型的开发
  • 批准号:
    3478617
  • 财政年份:
    1993
  • 资助金额:
    --
  • 项目类别:
DEVELOPMENT OF A MODEL FOR TAY-SACHS DISEASE
泰萨克斯病模型的开发
  • 批准号:
    2269096
  • 财政年份:
    1993
  • 资助金额:
    --
  • 项目类别:
DEVELOPMENT OF A MODEL FOR TAY-SACHS DISEASE
泰萨克斯病模型的开发
  • 批准号:
    3478616
  • 财政年份:
    1993
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了